hP1A8 + imiquimod + GBM6-AD

**hP1A8 + imiquimod + GBM6-AD** is an investigational combination therapy, currently in phase I clinical study, designed for the treatment of glioblastoma (GBM)[1][2][4]. It combines three distinct agents: - **hP1A8**: A humanized peptide analog of the CD200 activation receptor ligand (CD200AR-L), intended to stimulate immune activation primarily by binding to immuno-activating receptors on CD14+ myeloid cells, upregulating antigen-specific T-cell activity, dendritic cell maturation, and proinflammatory cytokine production. It is associated with reduced CD200R expression[1]. - **Imiquimod**: An FDA-approved small molecule immune response modifier acting as a toll-like receptor 7 agonist, used topically to stimulate innate and adaptive immunity via induction of cytokines. - **GBM6-AD vaccine**: An experimental vaccine based on GBM6 adenovirus targeting glioblastoma antigens to promote antitumor immunity[1]. The combination aims to enhance antitumor immune response in GBM by synergistic activation of innate and adaptive immune pathways. The phase I trial is sponsored by OX2 Therapeutics and is testing hP1A8’s efficacy, safety, and dose-range in combination with imiquimod and the GBM6-AD vaccine in adults with glioblastoma[1][2][4].

Other names

CD200AR-L (for hP1A8)GBM6-AD vaccineGBM-6-AD vaccineGBM 6-AD vaccine